Genome Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.30 M
- Revenue Growth 0.89%
- Profit Growth -22.84%
- Ebitda -77.45%
- Net Worth 27.81%
- Total Assets -1.29%
About Genome Therapeutics
Genome Therapeutics Private Limited (GTPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 July 2011 and has a history of 13 years and six months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.30 M.
Ravimohan Dhavala and Dhavala Madhavi serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2011PTC075543
-
Company No.
075543
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Jul 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Genome Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhavala Madhavi
|
Managing Director | 15-Jul-2011 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Ravimohan Dhavala
|
Whole-Time Director | 15-Jul-2011 | Current |
Financial Performance of Genome Therapeutics.
Genome Therapeutics Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.89% increase. The company also saw a substantial fall in profitability, with a 22.84% decrease in profit. The company's net worth Soared by an impressive increase of 27.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genome Therapeutics?
In 2020, Genome Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.30 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.63 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Dec 2012 | Others | ₹6.30 M | Open |
How Many Employees Work at Genome Therapeutics?
Unlock and access historical data on people associated with Genome Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genome Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
